Substance Misuse To Psychiatric Disorders for Cannabis

The University of Hong Kong37 enrolled

Overview

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Cannabis Use Disorder Depressive State Anxiety State Depression Anxiety Disorders Pharmacotherapy

Eligibility

Sex: ALLMin age: 16 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: • Cannabis use disorder with anxiety or depressive symptoms or disorders; or positive cannabis test results in 1 month with anxiety or depressive symptoms Exclusion Criteria: * Age \<16 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation * Had history of primary psychotic episode * Had been diagnosed to have substance-induced mood disorder, other than cannabis * Had been diagnosed to have mood disorders or anxiety disorders * Had been taking maintenance therapeutic dose of antidepressant continuously \>= 6 months AND with depressive symptom or anxiety symptom being in remission * Had known hypersensitivity to vortioxetine * Had known history of serotonin syndrome * Pregnant * Mother currently breast-feeding * Currently taking warfarin and/or having poorly controlled bleeding disorder * Had history of prolonged QTc ≥500ms and/or known unstable or untreated cardiology disease

Outcomes

Primary Outcomes

change in severity of Cannabis Use Disorder (CUD)

Change in severity of the cannabis use disorder for the 2 arms as defined by DSM-5

Time frame: 6 months

Secondary Outcomes

prevalence of Cannabis induced mood disorder

The prevalence of the cannabis induced disorder in both arms

Time frame: 6 months

Change in Hamilton anxiety (HAM-A) rating scale

To assess the change of anxiety severity of the two treatment arms using HAM-A for both treatment arms with cut-off of defining anxiety \>=14

Time frame: 6 months

Change in Hamilton depression (HAM-D) rating scale

To assess the change of depression severity of the two treatment arms using HAM-D for both treatment arms with cut-off of defining depression \>=8

Time frame: 6 months

Change in cognitive outcome

To assess the change in cognitive outcome using Frontal Assessment Battery in the two treatment arms

Time frame: 6 months

Substance Misuse To Psychiatric Disorders for Cannabis

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes